DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION:

Technology description follows.

Murine Cell Models for Metastatic Squamous Cell Carcinoma Two cell lines isolated from Pam 212 cells (SCC); Pam LY (lymph node metastasis) and Pam LU (lung metastasis) from metastasized in vivo growth in mouse. These stably established cell lines exhibited higher potential to metastasize to lymph nodes and lungs, respectively, in mouse models than their parental Pam 212 cells.

Potential Commercial Applications

• Drug discover for squamous cell carcinoma
• Drug discover for squamous cell carcinoma metastasized to lung and lymph nodes

Inventors: Zhong Chen and Carter Van Waes (both of NIDCD).


Licensing Contact: Michael Shmilovich, Esq. CLP: 301–435–5019; shmilovm@mail.nih.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Sustainable Technologies to Protect Human Health and the Environment

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION:

Technology description follows.

Mice (Mus musculus) were sacrified by decapitation and the liver and spleen were dissected and disaggregated in a 0.7% collagenase solution (Worthington Biochemical Corporation, Freehold, NJ) in PBS (P.B. Solutions, Inc., Branchburg, NJ). The organs were then washed in PBS and the cell-free supernatant was discarded. The remaining cell pellet was washed twice in PBS before 1.8 x 106 cells were injected i.p. into naive C57Bl/6 mice. The mice were sacrificed between 24 and 72 hours post injection and the lungs and lymph nodes were harvested.

Potential Commercial Applications

• Drug discover for squamous cell carcinoma
• Drug discover for squamous cell carcinoma metastasized to lung and lymph nodes

Inventors: Gary G. Small, Ph.D.; Henry R. Wahnert, Ph.D.; and Alphonse J. Condron, Ph.D.

Intellectual Property: The Biological collection of cell lines and associated research materials described herein are owned by the National Institute on Aging, National Institutes of Health.

Licensing Contact: Thomas J. Dickey, Ph.D., Office of Technology Transfer and Development, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579; fax: 301–402–8717; dickeyt@mail.nih.gov.